C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 312—Investigational New Drug ApplicationSubpart A—General Provisions

21 C.F.R. § 312.1 (2026)

Scope

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1978–2020 19citing cases
At a glance

Courts have cited this section in 19 opinions since 1978.

(a) This part contains procedures and requirements governing the use of investigational new drugs, including procedures and requirements for the submission to, and review by, the Food and Drug Administration of investigational new drug applications (IND's). An investigational new drug for which an IND is in effect in accordance with this part is exempt from the premarketing approval requirements that are otherwise applicable and may be shipped lawfully for the purpose of conducting clinical investigations of that drug.

(b) References in this part to regulations in the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.

The 19 cases that cite 21 C.F.R. § 312.1 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENRiegel v. Medtronic, Inc., 552 U.S. 312 (2008).
cites § 312.1 2×cited by 725 cases
Where it cites § 312.1
“§ 355 (i); 21 CFR § 312.1 et seq. (2007). Clinical trials generally proceed in three phases involving successively larger groups of patients: 20 to 80 subjects in phase I; no more than several hundred subjects in phase II; and several hundred to several thousand subjects in…”
The case’s holding
The Medical Device Amendments preclude state law claims that impose requirements different from, or in addition to, federal requirements regarding a device that received premarket approval.
Later courts cite it for
“360k does not prevent a state from providing a damages remedy for claims premised on a violation of fda regulations; the state duties in such a case 'parallel,' rather than add to, federal requirements.” · 102 citing courts
2
GREENUnited States v. Ronald C. Smith, 740 F.2d 734 (9th Cir. 1984).
cites § 312.1 4×cited by 21 cases
Where it cites § 312.1
“§§ 355 (i) and 331(e) in conjunction with 21 C.F.R. § 312.1 make it a crime for a clinical investigator to maintain inadequate or inaccurate records.”
Later courts cite it for
“a crime is complete when each element of the crime has occurred.” · 2 citing courts
3
cites § 312.1 1×cited by 93 cases
Where it cites § 312.1
“§355 (i); 21 CFR §312.1 et seq. (2005). 2 The IND must describe “preclinical tests (including tests on animals) of [the] drug adequate to justify the proposed clinical testing.”
The case’s holding
The patent infringement exemption under 35 U.{e}(1) covers all uses of patented inventions reasonably related to the development and submission of information under the Federal Food, Drug, and Cosmetic Act.
Later courts cite it for
“extends to all uses of patented inventions that are reasonably related to the development and submission of any information under the fdca.” · 10 citing courts
4
GREENUnited States v. An Article of Food, 678 F.2d 735 (7th Cir. 1982).
cites § 312.1 2×cited by 18 cases
Where it cites § 312.1
“355(i) and 21 CFR 312.1, has been accepted as adequate by the United States Food and Drug Administration.”
Later courts cite it for
“except when offered as a single ingredient for food use.” · 2 citing courts
5
GREENAsahi Kasei Pharma Corp. v. Actelion Ltd., 222 Cal. App. 4th 945 (Ct. App. 2013).
cites § 312.1 1×cited by 23 cases
Where it cites § 312.1
“( 21 C.F.R. § 312.1 et seq. (2013).) An IND for Fasudil had been approved by the FDA.”
Later courts cite it for
“a stranger,' as used in applied equipment means, one who is not a party to the contract or an agent of a party to the contract.” · 3 citing courts
6
GREENPeter H. Forsham v. Joseph A. Califano, Jr., 587 F.2d 1128 (D.C. Cir. 1978).
cites § 312.1 1×cited by 35 cases
Where it cites § 312.1
“21 C.F.R. § 312.1 (a)(12)(6)(e) gives the FDA the right of access to investigator’s records relating to investigational new drugs (INDs).”
The case’s holding
A federal agency cannot circumvent the Freedom of Information Act by transferring physical possession of its records to a warehouse or similar bailee.
Later courts cite it for
“a government agency cannot circumvent foia by transferring physical possession of its records to a warehouse or like bailee” · 1 citing court
7
GREENWhite v. Weiner, 562 A.2d 378 (Pa. 1989).
cites § 312.1 1×cited by 25 cases
Where it cites § 312.1
“§ 355 (b)(1)(A); see also 21 C.F.R. §§ 312.1 to 312.6. Additionally, after receiving approval, a manufacturer regularly must update its application with data or information, received or otherwise obtained by such applicant with respect to such drug, as the Secretary may by…”
The case’s holding
State law claims for failure to warn are subject to the same policy of deference to the federal drug labeling scheme as federal misbranding claims.
Later courts cite it for
“our legislature unequivocally has expressed a policy of deference to the federal scheme in the area of drug labeling, and we can ascertain no reason not to extend that policy to civil cases raising misbranding claims.” · 2 citing courts
8
cites § 312.1 2×cited by 7 cases
Where it cites § 312.1
“§ 355 (i) requires that records be maintained by manufacturers or sponsors of new drugs consistent with 21 C.F.R. § 312.1 (a) and Part 314. Those regulations require, inter alia, that the sponsor (1) maintain adequate records showing the investigator to whom the drug is shipped,…”
Later courts cite it for
“inadequate as a matter of law.” · 2 citing courts
9
GREENUnited States v. Sene X Eleemosynary Corp., 479 F. Supp. 970 (S.D. Fla. 1979).
cites § 312.1 1×cited by 21 cases
Where it cites § 312.1
“§ 355 (i) and 21 CFR 312.1, has been accepted as adequate by the Food and Drug Administration.”
10
GREENSchiff v. Prados, 92 Cal. App. 4th 692 (Ct. App. 2001).
cites § 312.1 1×cited by 8 cases
Where it cites § 312.1
“…of the federal act ( 21 U.S.C. § 355 (i)), which permits the drug to be clinically tested in humans (§ 109325; see 21 C.F.R. § 312.1 et seq. (2001)); or (3) specified alternative conditions, including filings with the Medical Board of California, are fulfilled (§§ 109300,…”
Later courts cite it for
“meaningful choice is at the heart of the informed consent doctrine” · 2 citing courts
11
GREENNutrilab, Inc. v. Schweiker, 547 F. Supp. 880 (N.D. Ill. 1982).
cites § 312.1 2×cited by 5 cases
Where it cites § 312.1
“355(i) and 21 C.F.R. 312.1, or (iii) the Food and Drug Administration has advised plaintiffs that the drug is not a “new drug”; (2) manufacturing, processing, packing, and labeling such articles of drug after shipment of one or more of their components in interstate commerce…”
12
GREENUnited States v. Undetermined Quantities of Articles of Drug, 145 F. Supp. 2d 692 (D. Md. 2001).
cites § 312.1 1×cited by 6 cases
Where it cites § 312.1
“§ 356© and 21 C.F.R. § 312.1 , has been accepted as adequate by the Food and Drug Administration; (B) Introducing or delivering for introduction into interstate commerce any such article of drug so long as the article is misbranded within the meaning of 21 U.”
13
GREENUnited States v. An Article of Device ... Diapulse, 768 F.2d 826 (7th Cir. 1985).
cites § 312.1 1×cited by 8 cases
Where it cites § 312.1
“See 21 C.F.R. § 312.1 (a)(12) and (13), forms FD-1572 and FD-1573 6g; 21 C.”
14
GREENUnited States v. Evers, 453 F. Supp. 1141 (M.D. Ala. 1978).
cites § 312.1 1×cited by 4 cases
Where it cites § 312.1
“The government contends that a physician or other person who ships or requests shipment of a prescription new drug in interstate commerce with the intent of applying it to an unapproved use, that person must first file with the Food and Drug Administration an investigational new…”
15
GREENEUSA Pharma (US), Inc. v. Innocoll Pharm. Ltd., 594 F. Supp. 2d 570 (E.D. Pa. 2009).
cites § 312.1 1×cited by 1 case
Where it cites § 312.1
“See 21 C.F.R. §§ 312.1 et seq. Before a sponsor may begin a clinical trial on human subjects, two requirements must be satisfied.”
16
NO FLAGGallagher v. Food & Drug Admin., No. 2018-2154 (D.D.C. Nov. 25, 2019).
cites § 312.1 1×cited by 0 cases
Where it cites § 312.1
“§ 355 (i); 21 C.F.R. § 312.1 . But Gallagher does not allege that he seeks to test, sell, or market a pharmaceutical drug.”
17
NO FLAGRae v. Child.'s Nat'l Med. Ctr., No. 2015-0736 (D.D.C. Dec. 28, 2020).
cites § 312.1 1×cited by 0 cases
Where it cites § 312.1
“14 ); two Code of Federal Regulations pertaining to investigational drug studies (21 C.F.R. 312.1, et seq and 42 C.F.R. 93.”
18
NO FLAGAsahi Kasei Pharma v. Actelion, No. A133927M (Cal. Ct. App. Jan. 16, 2014).
cites § 312.1 1×cited by 0 cases
Where it cites § 312.1
“( 21 C.F.R. § 312.1 et seq. (2013).) An IND for Fasudil had been approved by the FDA.”
19
NO FLAGDeVito v. Hem, Inc., 705 F. Supp. 1076 (M.D. Pa. 1989).
cites § 312.1 1×cited by 0 cases
Where it cites § 312.1
“§ 355 (i); 21 C.F.R. §§ 312.1 -.160 (1988). Plaintiff is a 38 year old man who has Acquired Immunodeficiency Syndrome (AIDS).”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
197819992020

One bar per year. Tallest: 2 cases in 1978. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Cal. Ct. App.3D.D.C.37th Cir.2SCOTUS2M.D. Ala.19th Cir.1D.C. Cir.1S.D. Fla.1

The 8 courts with the most citing cases, of 13 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com